Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 3
1963 3
1964 2
1965 5
1966 2
1968 1
1970 2
1971 1
1972 3
1973 3
1974 1
1984 1
1985 1
1991 1
1993 4
1994 1
1997 1
1999 1
2000 1
2001 4
2002 1
2003 3
2004 3
2005 5
2006 4
2007 6
2008 7
2009 3
2010 8
2011 3
2012 12
2013 21
2014 20
2015 25
2016 22
2017 24
2018 26
2019 32
2020 33
2021 30
2022 31
2023 31
2024 26
2025 21

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

377 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Palumbo A, et al. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. N Engl J Med. 2016. PMID: 27557302 Free article. Clinical Trial.
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.
D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE; LUCENT Study Group. D'Haens G, et al. N Engl J Med. 2023 Jun 29;388(26):2444-2455. doi: 10.1056/NEJMoa2207940. N Engl J Med. 2023. PMID: 37379135 Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group. Sandborn WJ, et al. N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617. N Engl J Med. 2021. PMID: 34587385 Clinical Trial.
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
Update on Cytomegalovirus Infection Management in Allogeneic Hematopoietic Stem Cell Transplant Recipients. A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC).
Piñana JL, Giménez E, Vázquez L, Marcos MÁ, Guerreiro M, Duarte R, Pérez A, de Miguel C, Espigado I, González-Vicent M, Suarez-Lledó M, García-Cadenas I, Martino R, Cedillo A, Rovira M, de la Cámara R, Navarro D, Solano C. Piñana JL, et al. Among authors: gimenez e. Mediterr J Hematol Infect Dis. 2024 Sep 1;16(1):e2024065. doi: 10.4084/MJHID.2024.065. eCollection 2024. Mediterr J Hematol Infect Dis. 2024. PMID: 39258183 Free PMC article. Review.
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.
Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B; PETHEMA/GEM Cooperative Group. Lasa M, et al. J Clin Oncol. 2025 Jan 10;43(2):125-132. doi: 10.1200/JCO.24.00635. Epub 2024 Oct 1. J Clin Oncol. 2025. PMID: 39353166
[Ten years of the cost-effectiveness threshold].
Giménez E, Rovira J, González JD, Aguiar R. Giménez E, et al. Farm Hosp. 2013 Mar-Apr;37(2):85-7. doi: 10.7399/FH.2013.37.2.376. Farm Hosp. 2013. PMID: 23789751 Spanish. No abstract available.
Stiff-Person Syndrome With Respiratory Complications.
Gimenez E, Sancho J, Signes-Costa J. Gimenez E, et al. Arch Bronconeumol. 2024 Mar;60(3):173-174. doi: 10.1016/j.arbres.2023.12.008. Epub 2023 Dec 20. Arch Bronconeumol. 2024. PMID: 38160164 English, Spanish. No abstract available.
377 results